Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-27T03:01:45.504Z Has data issue: false hasContentIssue false

Cholinesterase inhibitors and Alzheimer's disease

Published online by Cambridge University Press:  02 January 2018

Rafael Euba*
Affiliation:
Memorial Hospital, Shooters Hill, London SE18 3RZ, e-mail: Rafael.Euba@oxleas.nhs.uk
Rights & Permissions [Opens in a new window]

Abstract

Type
The columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2006. The Royal College of Psychiatrists

Simpson et al (Psychiatric Bulletin, November 2005, 29, 410-412) state in their audit of the use of cholinesterase inhibitors that stopping these drugs in the latest stages of dementia ‘ is poor clinical practice and likely to have adverse outcomes’. They base this opinion on the fact that many of the patients in their sample deteriorated or died after their memory enhancers were discontinued when their Mini-Mental State Examination scores fell below 12. The authors acknowledge that this high death rate could be because the patients who deteriorated or died were probably the most physically ill. In fact, this would be the simplest and most likely explanation. Therefore, the conclusion that stopping these drugs in the advanced stages of dementia constitutes poor clinical practice is really unfounded and could only be supported after the hypothesis is tested successfully in a controlled trial.

Submit a response

eLetters

No eLetters have been published for this article.